# Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

> **NCT00227617** · PHASE2,PHASE3 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 36 (actual)

## Conditions studied

- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
- Lung Cancer
- Neoplastic Syndrome
- Neuroendocrine Tumor

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** 5-fluorouracil
- **DRUG:** leucovorin
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00227617
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06-08
- **Primary completion:** 2012-01
- **Final completion:** 2016-02
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2023-05-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227617, "Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00227617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*